This presentation will emphasize the importance of risk stratification when treating patients with postmenopausal osteoporosis (PMO) at high or very high risk of fracture according to AACE guidelines for PMO. This presentation will also discuss when anabolic or antiresorptive therapy may be considered as an appropriate initial therapy option.
